Abstract
(2016). Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology: Vol. 26, No. 4, pp. 329-331.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology
Paper Title
Journal
Date
